❌

Normal view

Received — 18 September 2026 ⏭ Nature Medicine

Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma

✇Nature Medicine
By: Tara Barron · Richard Drexler · Aaron Mochizuki · Evan Cantor · Kiarash Shamardani · Pamelyn J. Woo · Neeraj Soni · Dana Tlais · Andrea Franson · Samantha Lyons · Truman Knowles · Shannon Raber · Vilina Mehta · Michael A. Quezada · Michael B. Keough · Samin Malaki Jahan · Linh Thuy Vo · Enrique Herrera Castañeda · Kathryn R. Taylor · Lijun Ni · Kim Kilian · Samuel H. Wu · Franz L. Ricklefs · Ulrich Schüller · Sabine Mueller · Paul G. Fisher · Cynthia J. Campen · Hannes Vogel · Sonia Partap · Kai Kaila · Carl Koschmann · Michelle Monje
17 September 2026 at 08:00

Nature Medicine, Published online: 17 September 2026; doi:10.1038/s41591-026-04646-6

Results of this study show in experimental models and data from patient cohorts that the antiseizure medication levetiracetam is associated with longer survival and reduced tumor growth in diffuse midline glioma, but not hemispheric high-grade glioma, by selectively dampening GABAergic synaptic signaling, independently of its canonical SV2A-mediated primary antiseizure mechanism.

EBV reactivation priming of the peripheral immune system in multiple sclerosis relapse

✇Nature Medicine
By: Devin A. King · Shrishti Saxena · Danielle Caefer · Kyle C. Downer · Laura E. Saucier · Ethan Goodman · Jonmichael Aracena · Alena Zhirova · Anthilia Alchanat · Saoirse Nolan · Hrishikesh Lokhande · Howard L. Weiner · Benjamin E. Gewurz · Tanuja Chitnis
16 September 2026 at 08:00

Nature Medicine, Published online: 16 September 2026; doi:10.1038/s41591-026-04665-3

Increased expression of EBV reactivation genes in B cells and MS risk genes targeted by the EBV protein EBNA-2 precedes MS attacks, linking EBV reactivation and genetic risk to the development of MS relapses.

Liquid biopsy for early detection of pancreatic ductal adenocarcinoma

✇Nature Medicine
By: Caiming Xu · Alessandro Mannucci · Haiyong Han · Ruben M. Munoz · Derek Cridebring · Sourat Darabi · Yuji Toiyama · Yoshinaga Okugawa · Gagandeep Singh · Mustafa Raoof · Joon Oh Park · James Lin · Gregory Idos · Michael J. Demeure · Erkut Borazanci · Douglas B. Evans · Susan Tsai · Eunsung Jun · Carlos Becerra · Scott A. Celinski · Laleh Melstrom · Vincent Chung · Guixin Zhang · Dong Shang · David L. Bartlett · Mitsuro Kanda · Song Cheol Kim · Valsamo Anagnastou · Giulia Martina Cavestro · John S. Bolton · Ali H. Zaidi · Daniel Von Hoff · Ajay Goel
16 September 2026 at 08:00

Nature Medicine, Published online: 16 September 2026; doi:10.1038/s41591-026-04625-x

In a prospective study involving 1,785 individuals from four countries, the PANXEON exosome-based biomarker, combined with carbohydrate antigen 19-9 levels, achieves high sensitivity for the detection of early-stage pancreatic cancer.

Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial

✇Nature Medicine
By: Feng Xue · Ai Zhang · Mankai Ju · Xia Wu · Bingqi Xu · Xiaolei Pei · Yuhua Wang · Wei Liu · Aiguo Liu · Wei Jiang · Xinyue Dai · Yunfei Chen · Xiaofan Liu · Rongfeng Fu · Ting Sun · Wenjing Gu · Jing Zheng · Zengmin Du · Caifeng Yang · Xiao Xiao · Renchi Yang · Qun Hu · Lei Zhang
16 September 2026 at 08:00

Nature Medicine, Published online: 16 September 2026; doi:10.1038/s41591-026-04636-8

In this single-arm phase 1 trial, an AAV gene therapy carrying the Padua variant of factor IX was well tolerated in 11 adolescents with hemophilia B and led to reductions in annualized bleeding rate.

Sex-specific biological aging clocks across organs and omics

✇Nature Medicine
By: Zhiyuan Song · Derek Feng · Naowal Azraf Rahman · Michael R. Duggan · Qu Tian · Jian Zeng · Xia Zhou · Chunrui Zou · Michael S. Rafii · Li Shen · Paul Thompson · Eleanor M. Simonsick · Keenan A. Walker · Andrew Zalesky · Christos Davatzikos · Paul Aisen · Luigi Ferrucci · Susan M. Resnick · Junhao Wen
16 September 2026 at 08:00

Nature Medicine, Published online: 16 September 2026; doi:10.1038/s41591-026-04662-6

Sex-specific biological aging clocks across multiple organs and molecular systems show that female and male aging patterns can differ in organ-specific, disease-relevant ways.

Beyond the breakthrough for RAS-driven cancers

✇Nature Medicine
By: Rich C. King · Erica S. Tsang · Jennifer J. Knox
15 September 2026 at 08:00

Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04610-4

Two early clinical studies of selective KRASG12D inhibitors show encouraging activity in advanced cancers with G12D mutations, signaling a transformative change in the treatment landscape for RAS-driven cancers with potential applications across tumor types and stages of disease.

On-premise medical AI agents for reliable clinical decision-making

✇Nature Medicine
By: Li Zhang · Georg Wölflein · Dyke Ferber · Junhao Liang · Zunamys I. Carrero · Xuewei Wu · Julien Vibert · Jan Clusmann · Lino Möhrmann · Elena E. Möhrmann · Catharina Wichmann · Fabian Wolf · Tim Lenz · Jakob Nikolas Kather
15 September 2026 at 08:00

Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04609-x

An autonomous clinical AI agent enhances decision-making through on-premise deployment and reliability metrics, achieving high diagnostic accuracy and selective autonomy.

Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial

✇Nature Medicine
By: Marcilio J. Fumagalli · Anna Kaczynska · Marius Allombert · Ágata Lopes-Ribeiro · Mariângela de Oliveira Silva · Brianna J. Hernandez · Christy Lavine · Sebastian M. Espinosa · Helen Brown · Hanna Box · Emanuela Falaschetti · Louise-Rae Cherrill · Tamara Elliott · Ming Lee · Julie Fox · Sarah Pett · Amanda Clarke · Alison Uriel · Ole Sogaard · Rebecca Sutherland · Marta Boffito · Sabine Kinloch-Loes · Chloe Orkin · Simon Collins · Panagiota Zacharopoulou · Nicola Robison · Cintia Bittar · Thiago Oliveira · Anna Gazumyan · Mila Jankovic · Michael S. Seaman · John Frater · Marina Caskey · Sarah Fidler · Michel C. Nussenzweig
15 September 2026 at 08:00

Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04644-8

In the phase 2 RIO trial, there was delayed viral rebound and resistance to broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS in adult males living with HIV undergoing analytical treatment interruption, and initial reservoir sensitivity to autologous antibodies was associated with a longer time to rebound.
Received — 15 September 2026 ⏭ Nature Medicine
  • ✇Nature Medicine
  • De novo mutations bridge parental reproductive factors and offspring health
    Nature Medicine, Published online: 14 September 2026; doi:10.1038/s41591-026-04676-0Whole-genome sequencing of 7,851 parent–offspring families enabled the identification of parent-of-origin and post-zygotic de novo mutations that were associated with distinct procedures of assisted reproductive technology (ART), independently of parental age at conception. Increased paternal mutational burden statistically mediates the effects of advanced parental age and ART on gestational duration and other bi
     
  • 🏷️
  • ↗️

De novo mutations bridge parental reproductive factors and offspring health

✇Nature Medicine
14 September 2026 at 08:00

Nature Medicine, Published online: 14 September 2026; doi:10.1038/s41591-026-04676-0

Whole-genome sequencing of 7,851 parent–offspring families enabled the identification of parent-of-origin and post-zygotic de novo mutations that were associated with distinct procedures of assisted reproductive technology (ART), independently of parental age at conception. Increased paternal mutational burden statistically mediates the effects of advanced parental age and ART on gestational duration and other birth outcomes.

Rethinking the global health system for a new international order

✇Nature Medicine
By: Kumanan Rasanathan · Keith Cloete · Githinji Gitahi · Octavio Gómez Dantés · Hajime Inoue · Catherine Kyobutungi · Giulia Loffreda · Ntobeko A. B. Ntusi · Kelechi Ohiri · Minghui Ren · Diah Saminarsih · Soumya Swaminathan · Amirhossein Takian · Viroj Tangcharoensathien · John-Arne Røttingen
14 September 2026 at 08:00

Nature Medicine, Published online: 14 September 2026; doi:10.1038/s41591-026-04622-0

In this Comment, we argue for a global health system that recognizes and supports countries as the primary agents of action, oriented around global public goods and collective action, and served by a leaner set of global and regional institutions. We present a potential vision for the functions and distribution of labor in the system to inform ongoing reform discussions and draw critique, dissent and amendment.

Prospective evidence for conversational medical AI is hard, but non-negotiable

✇Nature Medicine
By: Mike Schaekermann · Anil Palepu · Adam Rodman · Ami Parekh · Ethan Goh · Shekoofeh Azizi · Yun Liu · Sunny Virmani · Christina Chen · Dale R. Webster · Joëlle Barral · Avinatan Hassidim · Yossi Matias · Po-Hsuan Cameron Chen
14 September 2026 at 08:00

Nature Medicine, Published online: 14 September 2026; doi:10.1038/s41591-026-04639-5

Trust in clinical artificial intelligence (AI) cannot be benchmarked into existence. It must be earned through rigorous prospective studies in real-world clinical settings, where the hardest lessons often concern the humans and systems around the AI, not the technology itself.
Received — 13 September 2026 ⏭ Nature Medicine

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

✇Nature Medicine
By: Arsela Prelaj · Vanja Miskovic · Matteo Sacco · Alberto Ferrarin · Cristina Maria Licciardello · Leonardo Provenzano · Margherita Favali · Ludovica Lerma · Aleksandra Zec · Andrea Spagnoletti · Monica Ganzinelli · Daniele Lorenzini · Beshoy Guirges · Luca Invernizzi · Cecilia Silvestri · Laura Mazzeo · Marco Meazza Prina · Giulia Corrao · Margherita Ruggirello · Andra Diana Dumitrascu · Rosa Maria Di Mauro · Dario Monzani · Gabriella Pravettoni · Michele Zanitti · Davide Macocchi · Moreno Bruno Marino · Chiara Cavalli · Rebecca Romanò · Claudia Giani · Samuel G. Armato III · Alessandra Esposito · Christine M. Bestvina · Maria Spector · Bogot R. Naama · Reham Basheer · Adi Lahiani Hafzadi · Laila Roisman · Iris Watermann · Marlen Szewczyk · Till Olchers · Heinz Richter · Constantin Blanke-Roeser · Costanza Siniscalchi · Anna Di Lello · Teresa Arangoa · Valentina Bartolomeo · Nikolaos Spathas · Evangelos Sarris · Elena Fountzilas · Aina Arbusà Roca · Rocio Caro-Consuegra · Patricia Iranzo · Melissa Fernández-Pinto · Jose Rodríguez-Morató · Luca Agnelli · Mari
13 September 2026 at 08:00

Nature Medicine, Published online: 13 September 2026; doi:10.1038/s41591-026-04488-2

In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.

A global digital navigator of human health for precision medicine

✇Nature Medicine
By: Kang Zhang · Jiahong Dong · Hang Wong · Sian Liu · Kai Wang · Wei Wu · Kaixin Zhou · Kanmin Xue · Edward Zhang · Jonathan Gootenberg · Omar O. Abudayyeh · Michelle Williams · Xian Shen · Alexandre Loupy · Trey Ideker · Patrick Tan · Joseph Wu · Akrit Sodhi · Eric Oermann · Tao Xu · Guang Ning
11 September 2026 at 08:00

Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04621-1

The International Consortium of Digital Twins in Healthcare and Medicine was established to advance medical digital twin technology as a new infrastructure for precision health.

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

✇Nature Medicine
By: Omar Nadeem · David M. Cordas dos Santos · Sophie Magidson · Jeffrey Matous · Eva Medvedova · Elizabeth O’Donnell · Robert A. Redd · Yuxin Liu · Shonali Midha · Adam S. Sperling · Frances Arters · Christine Davie · Caroline Ricciardi · Rosa Toenges · Nayda Bidikian · Subear Hussein · Jean-Baptiste Alberge · Sungjae Kim · Lorena Pantano-Rubino · Francesco Corrado · Hannah Ashton · Daniel Addonizio · Siham Mohamed · Ashlee Sturtevant · Marjorie Marto · Amy Bergeron · Francesco Malfona · Kevin Panaro · Paul G. Richardson · Jerome Ritz · Lorenzo Trippa · Irene M. Ghobrial
11 September 2026 at 08:00

Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04642-w

In the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment with teclistamab compared with lenalidomide–dexamethasone, although longer follow-up is required to determine durable prevention of progression to MM.

Joint impact of pathological burden and cognitive resilience on Alzheimer’s disease risk

✇Nature Medicine
By: Zhibo Wang · Shuheng Wang · Yumei Liang · Xinlei Chen · Simiao Wang · Wei Qin · Qi Wang · Yan Li · Tan Zhao · Yue Wang · Fang Li · Guoguang Zhao · Jianping Jia
11 September 2026 at 08:00

Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04635-9

A 15-year cohort study shows that Alzheimer’s dementia risk is jointly shaped by Alzheimer’s pathology and cognitive resilience, with high resilience linked to lower risk, even under greater pathology.

A clinically-oriented foundation model for intraoperative pathology

✇Nature Medicine
By: Zihan Zhao · Fengtao Zhou · Ronggang Li · Bing Chu · Xinke Zhang · Xueyi Zheng · Ke Zheng · Xiaobo Wen · Jiabo Ma · Yihui Wang · Jiewei Chen · Chengyou Zheng · Jiangyu Zhang · Yongqin Wen · Jiajia Meng · Ziqi Zeng · Xiaoqing Li · Jing Li · Dan Xie · Yaping Ye · Yu Wang · Hao Chen · Muyan Cai
10 September 2026 at 08:00

Nature Medicine, Published online: 10 September 2026; doi:10.1038/s41591-026-04703-0

CRISP, a vision-based pathology foundation model developed exclusively from frozen section slides, supports treatment decision-making throughout the surgical workflow with superior performance to current foundation models and extensive validation, including in a prospective cohort.

Computable longitudinal patient journeys from structured and unstructured EHR data

✇Nature Medicine
By: Edward Kim · Richard Foty · Avnesh S. Thakor · Jay S. Skyler · Lucy F. Robinson · James D. Park · Monica Kraft · Charles B. Cairns · Vicki Seyfert-Margolis
10 September 2026 at 08:00

Nature Medicine, Published online: 10 September 2026; doi:10.1038/s41591-026-04695-x

A suite of large pre-trained language models accurately extracts computable clinical data from unstructured electronic health records and integrates the findings into knowledge graphs that can facilitate understanding patient trajectories and treatment responses in the real world.

Our Future Health and the next generation of population medicine

✇Nature Medicine
By: Zhonghan Sun · Yan Zheng
10 September 2026 at 08:00

Nature Medicine, Published online: 10 September 2026; doi:10.1038/s41591-026-04596-z

An early assessment of the UK’s Our Future Health project shows how national-scale cohorts may reshape population medicine by accelerating discovery and clinical recruitment, provided that selection and phenotyping biases are carefully measured and managed.
Received — 10 September 2026 ⏭ Nature Medicine

Author Correction: Ablation of <i>TRIP-Br2</i>, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance

✇Nature Medicine
By: Chong Wee Liew · Jeremie Boucher · Jit Kong Cheong · Cecile Vernochet · Ho-Jin Koh · Cristina Mallol · Kristy Townsend · Dominique Langin · Dan Kawamori · Jiang Hu · Yu-Hua Tseng · Marc K Hellerstein · Stephen R Farmer · Laurie Goodyear · Alessandro Doria · Matthias Blüher · Stephen I-Hong Hsu · Rohit N Kulkarni
9 September 2026 at 08:00

Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04678-y

Author Correction: Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance
❌